Immunovant (IMVT) Change in Account Payables (2019 - 2026)

Immunovant (IMVT) has 8 years of Change in Account Payables data on file, last reported at -$1.3 million in Q1 2026.

• Quarterly Change in Account Payables rose 41.45% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.3 million (down 195.96% YoY) and the FY2026 annual result came in at -$10.3 million, down 195.96% from the prior year.
• Change in Account Payables eased to -$1.3 million in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $25.0 million in Q2 2023 to a low of -$18.9 million in Q3 2023.
• A 5-year average of $1.2 million and a median of $1.6 million in 2025 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 1727.02% in 2022, down 2690.37% in 2022.
• Tracing IMVT's Change in Account Payables over 5 years: stood at $6.5 million in 2022, then slumped by 157.23% to -$3.7 million in 2023, then surged by 92.98% to -$260000.0 in 2024, then surged by 701.15% to $1.6 million in 2025, then sank by 186.31% to -$1.3 million in 2026.
• The last three Change in Account Payables figures came in at -$1.3 million (Q1 2026), $1.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.